Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial

Authors: André, Thierry ^{a, b, *}, Elez, Elena ^c, Lenz, Heinz-Josef ^d, Jensen, Lars Henrik ^e, Touchefeu, Yann ^f, Van Cutsem, Eric ^g, Garcia-Carbonero, Rocio ^h, Tougeron, David ⁱ, Mendez, Guillermo Ariel ^j, Schenker, Michael ^{k, l}, de la Fouchardiere, Christelle ^m, Limon, Maria Luisa ⁿ, Yoshino, Takayuki ^o, Li, Jin ^p, Manzano Mozo, Jose Luis ^q, Dahan, Laetitia ^r, Tortora, Giampaolo ^s, Chalabi, Myriam ^t, Goekkurt, Eray ^u, Braghiroli, Maria Ignez ^v, Joshi, Rohit ^w, Cil, Timucin ^x, Aubin, Francine ^y, Cela, Elvis ^z, Chen, Tian ^z, Lei, Ming ^z, Jin, Lixian ^z, Blum, Steven I ^z, Lonardi, Sara ^aa

Source: In The Lancet 1-7 February 2025 405(10476):383-395

The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC

Authors: Gray, Jhanelle E. ^{a, ∗}, Schenker, Michael ^b, Şendur, Mehmet Ali Nahit ^c, Leonova, Viktoriya ^d, Kowalski, Dariusz ^e, Kato, Terufumi ^f, Orlova, Rashida ^g, Yang, James Chih-Hsin ^h, Langleben, Adrian ⁱ, Pilz, Arnold ^j, Ungureanu, Andrei ^k, Mak, Milena Perez ^l, De Angelis, Flavia ^m, Aggarwal, Himani ⁿ, Zimmer, Zachary ⁿ, Zhao, Bin ⁿ, Shamoun, Mark ⁿ, Kim, Tae Min ^o

Source: In Journal of Thoracic Oncology February 2025 20(2):219-232

Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy

Authors: Hochmair, Maximilian ^a, Schenker, Michael ^b, Cobo Dols, Manuel ^c, Kim, Tae Min ^d, Ozyilkan, Ozgur ^e, Smagina, Maria ^f, Leonova, Viktoriya ^g, Kato, Terufumi ^h, Fedenko, Alexander ⁱ, De Angelis, Flavia ^j, Rittmeyer, Achim ^k, Gray, Jhanelle E. ^l, Greystoke, Alastair ^m, Aggarwal, Himani ⁿ, Huang, Qinlei ⁿ, Zhao, Bin ⁿ, Lara-Guerra, Humberto ⁿ, Nadal, Ernest ^{o, ∗}

Source: In Journal of Thoracic Oncology February 2025 20(2):203-218

Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis

Authors: Peters, Solange ^{a, ∗}, Paz-Ares, Luis G. ^b, Reck, Martin ^c, Carbone, David P. ^d, Brahmer, Julie R. ^e, Borghaei, Hossein ^f, Lu, Shun ^g, O’Byrne, Kenneth J. ^h, John, Thomas ⁱ, Ciuleanu, Tudor-Eliade ^j, Schenker, Michael ^k, Bernabe Caro, Reyes ^l, Nishio, Makoto ^m, Cobo, Manuel ⁿ, Lee, Jong-Seok ^o, Zurawski, Bogdan ^p, Pluzanski, Adam ^q, Aoyama, Takekazu ^r, Tschaika, Marina ^s, Devas, Vipul ^t, Grootendorst, Diederik J. ^u, Ramalingam, Suresh S. ^v

Source: In Journal of Thoracic Oncology January 2025 20(1):94-108

Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial

Authors: Reck, Martin, Ciuleanu, Tudor-Eliade, Schenker, Michael, Bordenave, Stephanie, Cobo, Manuel, Juan-Vidal, Oscar, Reinmuth, Niels, Richardet, Eduardo, Felip, Enriqueta, Menezes, Juliana, Cheng, Ying, Mizutani, Hideaki, Zurawski, Bogdan, Alexandru, Aurelia, Carbone, David P., Lu, Shun, John, Thomas, Aoyama, Takekazu, Grootendorst, Diederik J., Hu, Nan, Eccles, Laura J., Paz-Ares, Luis G.

Source: In European Journal of Cancer November 2024 211

First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial

Authors: Özgüroğlu, Mustafa, Kilickap, Saadettin, Sezer, Ahmet, Gümüş, Mahmut, Bondarenko, Igor, Gogishvili, Miranda, Nechaeva, Marina, Schenker, Michael, Cicin, Irfan, Ho, Gwo Fuang, Kulyaba, Yaroslav, Zyuhal, Kasimova, Scheusan, Roxana-Ioana, Garassino, Marina Chiara, He, Xuanyao, Kaul, Manika, Okoye, Emmanuel, Li, Yuntong, Li, Siyu, Pouliot, Jean-Francois, Seebach, Frank, Lowy, Israel, Gullo, Giuseppe, Rietschel, Petra

Source: Lancet oncology. 24(9):989-1001

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100196081289.0x000001&indx=1&recIds=ETOCvdc_100196081289.0x000001

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes

Authors: Reck, Martin, Ciuleanu, Tudor-Eliade, Cobo, Manuel, Schenker, Michael, Zurawski, Bogdan, Menezes, Juliana, Richardet, Eduardo, Bennouna, Jaafar, Felip, Enriqueta, Juan-Vidal, Oscar, Alexandru, Aurelia, Cheng, Ying, Sakai, Hiroshi, Paz-Ares, Luis, Lu, Shun, John, Thomas, Sun, Xiaowu, Moisei, Aniela, Taylor, Fiona, Lawrance, Rachael, Zhang, Xiaoqing, Sylvester, Judi, Yuan, Yong, Blum, Steven I., Penrod, John R., Carbone, David P.

Source: European journal of cancer. 183:174-187

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100190699417.0x000001&indx=1&recIds=ETOCvdc_100190699417.0x000001

Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summary

Authors: Bajorin, Dean F, Witjes, J Alfred, Gschwend, Jürgen E, Schenker, Michael, Valderrama, Begoña P, Tomita, Yoshihiko, Bamias, Aristotelis, Lebret, Thierry, Shariat, Shahrokh F., Park, Se Hoon, Ye, Dingwei, Agerbaek, Mads, Enting, Deborah, McDermott, Ray, Gajate, Pablo, Peer, Avivit, Milowsky, Matthew I, Nosov, Alexander, Antonio, João Neif, Tupikowski, Krzysztof, Toms, Laurence, Fischer, Bruce S, Qureshi, Anila, Collette, Sandra, Unsal-Kacmaz, Keziban, Broughton, Edward, Zardavas, Dimitrios, Koon, Henry B, Galsky, Matthew D

Source: Future oncology. 19(6):413-426

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100189950669.0x000001&indx=1&recIds=ETOCvdc_100189950669.0x000001

A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus

Authors: Janjigian, Yelena Y, Shitara, Kohei, Moehler, Markus, Garrido, Marcelo, Salman, Pamela, Wyrwicz, Lucjan, Yamaguchi, Kensei, Skoczylas, Tomasz, Bragagnoli, Arinilda Campos, Liu, Tianshu, Schenker, Michael, Yanez, Patricio, Tehfe, Mustapha, Kowalyszyn, Ruben, Karamouzis, Michalis V, Bruges, Ricardo, Zander, Thomas, Pazo-Cid, Roberto, Hitre, Erika, Feeney, Kynan, Cleary, James M, Poulart, Valerie, Cullen, Dana, Lei, Ming, Xiao, Hong, Kondo, Kaoru, Li, Mingshun, Ajani, Jaffer A

Source: Future oncology. 19(11):739-752

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100189941663.0x000001&indx=1&recIds=ETOCvdc_100189941663.0x000001

Comprehensive preoperative psychological assessment of breast cancer patients

Authors: Schenker, Ramona Adriana, Schenker, Michael, Stovicek, Puiu Olivian, Mazilu, Laura, Negru, Șerban Mircea, Burov, Georgeta, Ciurea, Marius Eugen

Source: Psychology, health & medicine. 28(2):359-374

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173244907.0x000001&indx=1&recIds=ETOCvdc_100173244907.0x000001

Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1

Authors: Reck, Martin, Ciuleanu, Tudor-Eliade, Lee, Jong-Seok, Schenker, Michael, Zurawski, Bogdan, Kim, Sang-We, Mahave, Mauricio, Alexandru, Aurelia, Peters, Solange, Pluzanski, Adam, Caro, Reyes Bernabe, Linardou, Helena, Burgers, Jacobus A., Nishio, Makoto, Martinez-Marti, Alex, Azuma, Koichi, Axelrod, Rita, Paz-Ares, Luis G., Ramalingam, Suresh S., Borghaei, Hossein, O’Byrne, Kenneth J., Li, Li, Bushong, Judith, Gupta, Ravi G., Grootendorst, Diederik J., Eccles, Laura J., Brahmer, Julie R.

Source: In Journal of Thoracic Oncology August 2023 18(8):1055-1069

Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria

Authors: Larkin, James, Weber, Jeffrey, Del Vecchio, Michele, Gogas, Helen, Arance, Ana M., Dalle, Stephane, Cowey, C. Lance, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Márquez-Rodas, Iván, Butler, Marcus O., Di Giacomo, Anna Marie, Middleton, Mark R., De la Cruz-Merino, Luis, Arenberger, Petr, Atkinson, Victoria, Hill, Andrew, Fecher, Leslie A., Millward, Michael, Khushalani, Nikhil I., Queirolo, Paola, Long, Georgina V., Lobo, Maurice, Askelson, Margarita, Ascierto, Paolo A., Mandalá, Mario

Source: European journal of cancer. 173:285-296

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100195212963.0x000001&indx=1&recIds=ETOCvdc_100195212963.0x000001

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)

Authors: Monk, Bradley J., Parkinson, Christine, Lim, Myong Cheol, O'Malley, David M., Oaknin, Ana, Wilson, Michelle K., Coleman, Robert L., Lorusso, Domenica, Bessette, Paul, Ghamande, Sharad, Christopoulou, Athina, Provencher, Diane, Prendergast, Emily, Demirkiran, Fuat, Mikheeva, Olga, Yeku, Oladapo, Chudecka-Glaz, Anita, Schenker, Michael, Littell, Ramey D., Safra, Tamar, Chou, Hung-Hsueh, Morgan, Mark A., Drochýtek, Vít, Barlin, Joyce N., Van Gorp, Toon, Ueland, Fred, Lindahl, Gabriel, Anderson, Charles, Collins, Dearbhaile C., Moore, Kathleen, Marme, Frederik, Westin, Shannon N., McNeish, Iain A., Shih, Danny, Lin, Kevin K., Goble, Sandra, Hume, Stephanie, Fujiwara, Keiichi, Kristeleit, Rebecca S.

Source: Journal of clinical oncology. 40(34):3952-3964

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173119109.0x000001&indx=1&recIds=ETOCvdc_100173119109.0x000001

Treatment of advanced urothelial cancer with nivolumab plus chemotherapy versus chemotherapy alone (CheckMate 901 study): a plain language summary.

Authors: van der Heijden, Michiel S, Sonpavde, Guru, Powles, Thomas, Necchi, Andrea, Burotto, Mauricio, Schenker, Michael, Sade, Juan Pablo, Bamias, Aristotelis, Beuzeboc, Philippe, Bedke, Jens, Oldenburg, Jan, Chatta, Gurkamal, Ürün, Yüksel, Ye, Dingwei, He, Zhisong, Valderrama, Begoña P, Ku, Ja Hyeon, Tomita, Yoshihiko, Filian, Jeiry, Wang, Lily

Source: Future Oncology; Mar2025, Vol. 21 Issue 6, p605-616, 12p

Adjuvant nivolumab (NIVO) vs placebo (PBO) for high-risk muscle-invasive urothelial carcinoma (MIUC): Additional efficacy outcomes including overall survival (OS) in patients (pts) with muscle-invasive bladder cancer (MIBC) from CheckMate 274.

Authors: Milowsky, Matthew I., Galsky, Matthew D., Witjes, Johannes Alfred, Gschwend, Jürgen E., Schenker, Michael, Perez Valderrama, Begona, Tomita, Yoshihiko, Bamias, Aristotelis, Lebret, Thierry, Shariat, Shahrokh F., Park, Se Hoon, Agerbaek, Mads, Jha, Gautam Gopalji, Stenner, Frank, Ye, Dingwei, Giudici, Fabio, Connors, Jessica, Zhang, Joshua, Bajorin, Dean F.

Source: Journal of Clinical Oncology; 2/20/2025 Supplement 5, Vol. 43, p658-658, 242p

First results of nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) from CheckMate 8HW.

Authors: Andre, Thierry, Elez, Elena, Lenz, Heinz-Josef, Jensen, Lars Henrik, Touchefeu, Yann, Van Cutsem, Eric, Garcia-Carbonero, Rocio, Tougeron, David, Mendez, Guillermo, Schenker, Michael, De La Fouchardiere, Christelle, Limon, Maria Luisa, Yoshino, Takayuki, Li, Jin, Aubin, Francine, Cela, Elvis, Chen, Tian, Lei, Ming, Jin, Lixian, Lonardi, Sara

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, pLBA143-LBA143, 10p

Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) therapy for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW expanded analyses.

Authors: Kudo, Masatoshi, Yau, Thomas, Decaens, Thomas, Sangro, Bruno, Qin, Shukui, Da Fonseca, Leonardo, Karachiwala, Hatim, Park, Joong-Won, Gane, Edward, Pinter, Matthias, Tai, David, Santoro, Armando, Pizarro, Gonzalo, Chiu, Chang-Fang, Schenker, Michael, He, Aiwu Ruth, Hu, Nan, Jimenez Exposito, Maria Jesus, Stromko, Caitlyn, Galle, Peter Robert

Source: Journal of Clinical Oncology; 2025 Supplement 4, Vol. 43, p520-520, 132p

Clinically Significant BRCA1 and BRCA2 Germline Variants in Breast Cancer—A Single-Center Experience.

Authors: Pleșea, Răzvan Mihail, Riza, Anca-Lelia, Ahmet, Ana Maria, Gavrilă, Ionuț, Mituț, Andreea, Camen, Georgiana-Cristiana, Lungulescu, Cristian Virgil, Dorobanțu, Ștefania, Barbu, Adina, Grigorescu, Andra, Mirea, Cecil Sorin, Schenker, Michael, Burada, Florin, Streață, Ioana

Source: Cancers; Jan2025, Vol. 17 Issue 1, p39, 20p

Subject Terms: RISK assessment, STATISTICAL correlation, CANCER treatment, BRCA genes, GERM cells, RESEARCH funding, BREAST tumors, FISHER exact test, GENETIC carriers, CHI-squared test, GENETIC risk score, IMMUNOHISTOCHEMISTRY, RESEARCH, GENETIC mutation, COMPARATIVE studies, GENETIC testing, GENOTYPES, PHENOTYPES, SPECIALTY hospitals, SYMPTOMS

Geographic Terms: ROMANIA

Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274.

Authors: Galsky, Matthew D., Witjes, Johannes Alfred, Gschwend, Jürgen E., Milowsky, Matthew I., Schenker, Michael, Valderrama, Begoña P., Tomita, Yoshihiko, Bamias, Aristotelis, Lebret, Thierry, Shariat, Shahrokh F., Park, Se Hoon, Agerbaek, Mads, Jha, Gautam, Stenner, Frank, Ye, Dingwei, Giudici, Fabio, Dutta, Santanu, Askelson, Margarita, Nasroulah, Federico, Zhang, Joshua

Source: Journal of Clinical Oncology; 1/1/2025, Vol. 43 Issue 1, p15-21, 9p

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Authors: Paz-Ares, Luis G., Ramalingam, Suresh S., Ciuleanu, Tudor-Eliade, Lee, Jong-Seok, Urban, Laszlo, Caro, Reyes Bernabe, Park, Keunchil, Sakai, Hiroshi, Ohe, Yuichiro, Nishio, Makoto, Audigier-Valette, Clarisse, Burgers, Jacobus A., Pluzanski, Adam, Sangha, Randeep, Gallardo, Carlos, Takeda, Masayuki, Linardou, Helena, Lupinacci, Lorena, Lee, Ki Hyeong, Caserta, Claudia, Provencio, Mariano, Carcereny, Enric, Otterson, Gregory A., Schenker, Michael, Zurawski, Bogdan, Alexandru, Aurelia, Vergnenegre, Alain, Raimbourg, Judith, Feeney, Kynan, Kim, Sang-We, Borghaei, Hossein, O'Byrne, Kenneth John, Hellmann, Matthew D., Memaj, Arteid, Nathan, Faith Ellen, Bushong, Judith, Tran, Phuong, Brahmer, Julie R., Reck, Martin

Source: In Journal of Thoracic Oncology February 2022 17(2):289-308